Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $55.00

Tandem Diabetes Care (NASDAQ:TNDM) had its target price increased by Barclays from $39.00 to $55.00 in a note issued to investors on Monday, Benzinga reports. The firm presently has an “overweight” rating on the medical device company’s stock. Barclays‘s target price would indicate a potential upside of 25.00% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. Leerink Partnrs upgraded Tandem Diabetes Care from a “market perform” rating to an “outperform” rating in a research note on Thursday, April 25th. Robert W. Baird raised their price target on shares of Tandem Diabetes Care from $28.00 to $36.00 and gave the company a “neutral” rating in a report on Friday, May 3rd. Citigroup boosted their price objective on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus raised their target price on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, April 23rd. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $50.00 price target (up from $35.00) on shares of Tandem Diabetes Care in a report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $43.80.

Tandem Diabetes Care Stock Performance

TNDM stock opened at $44.00 on Monday. The company has a debt-to-equity ratio of 1.43, a current ratio of 3.81 and a quick ratio of 3.01. Tandem Diabetes Care has a 1-year low of $13.82 and a 1-year high of $47.00. The business has a 50-day moving average price of $32.91 and a 200 day moving average price of $26.53. The company has a market capitalization of $2.84 billion, a P/E ratio of -20.28 and a beta of 1.10.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The business had revenue of $196.80 million during the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. As a group, equities research analysts forecast that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Sei Investments Co. increased its stake in Tandem Diabetes Care by 125.8% during the 1st quarter. Sei Investments Co. now owns 17,349 shares of the medical device company’s stock worth $614,000 after buying an additional 9,666 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in Tandem Diabetes Care in the 1st quarter valued at $1,335,000. Lisanti Capital Growth LLC lifted its holdings in Tandem Diabetes Care by 65.1% in the 1st quarter. Lisanti Capital Growth LLC now owns 174,830 shares of the medical device company’s stock valued at $6,191,000 after purchasing an additional 68,935 shares in the last quarter. Oppenheimer Asset Management Inc. lifted its holdings in Tandem Diabetes Care by 49.0% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 40,380 shares of the medical device company’s stock valued at $1,430,000 after purchasing an additional 13,277 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Tandem Diabetes Care during the 1st quarter worth $5,227,000.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.